Group 1 - Constellium SE held its Annual General Meeting of Shareholders on May 15, 2025, and published the voting results on its website [1] - All proposals at the AGM were adopted, including the appointment of Bradley Soultz and the re-appointment of Emmanuel Blot, Martha Brooks, and Lori Walker to the Board of Directors for a three-year term [2] - Constellium is a global leader in developing innovative, value-added aluminum products for various markets, generating $7.3 billion in revenue in 2024 [3]

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced the results of its Combined Shareholders' Meeting [1][12] - The meeting took place on May 22, 2025, in Paris, chaired by CEO Frédéric Cren [2] - All resolutions were adopted except for the 33rd resolution, which was negatively recommended by the Board of Directors [3] Voting Results - The shareholders present included 245 participants, representing a total of 90,772,892 shares and 102,984,957 votes, achieving a quorum of 65.264% [5] - Ordinary resolutions were overwhelmingly adopted, with the first resolution receiving 99.98% approval [6][10] - The 33rd resolution, which would have allowed the Board to decide on share capital increases for a company savings plan, was rejected with 90.58% against [10][11] Company Overview - Inventiva is publicly listed on Euronext Paris and Nasdaq, focusing on the research and development of oral small molecule therapies for MASH and other unmet medical needs [12][13] - The company is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial for MASH treatment [12]

Core Insights - The founding team of PillPack has launched a new company called General Medicine, aiming to simplify the medical care experience to be as easy as online shopping [1] - General Medicine is an online healthcare marketplace that connects users with providers based on specific medical needs and allows for symptom discussions [2] - The platform supports a variety of health needs, including prescription services and specialist location, with payment options including cash and insurance [2] Company Overview - General Medicine utilizes a combination of its own medical groups, networks of specialists, and local providers, clinics, and labs to deliver healthcare services [3]

Core Insights - Fresenius Medical Care (FME) successfully executed its strategic plan during the 2024 fiscal year, laying a strong foundation for sustainable and profitable growth [1][2] - The company completed its first full fiscal year as a stock corporation, achieving significant milestones in debt reduction and operational realignment [2] - The company reported a 4% organic revenue growth and an 18% increase in operating income, positioning itself for double-digit earnings growth in 2025 [3] Financial Performance - The Care Delivery segment achieved a margin contribution of over 10%, reaching the lower end of its target band of 10-14% [2] - Care Enablement demonstrated a strong margin performance of 6.1% in 2024, nearly tripling its prior year contribution and entering its target margin band of 8-12% in Q1 2025 [2] - The company set a new savings target of 750 million Euro for its FME25 transformation program, a 50% increase from the original target of 500 million Euro [2] Shareholder Returns - A dividend of 1.44 Euro per share was approved, representing a 21% increase from the previous year and marking the highest dividend in the company's history [2][3] - 96.85% of shareholders approved the proposed dividend at the Annual General Meeting [2] Corporate Governance - The compensation report for the Management Board and Supervisory Board was approved with a majority of 88.57% [3] - Authorizations for the Management Board to increase share capital and issue option or convertible bonds were renewed, allowing for flexible financing options [5][4] Market Position - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally [7] - The company operates 3,674 dialysis clinics and is recognized for its innovative dialysis products, including the FDA-approved 5008X machine for high-volume hemodiafiltration dialysis therapy [2][7]

今年，这份全球商界女性领袖的权威榜单迈入第28个年头。这份榜单既揭晓了当下最具有影响力的领导 者，也展示了未来有望攀登更高峰的潜力者。 "全球最具影响力的商界女性榜单"历来以数据为导向，依据高管所在企业规模、运营状况或损益表进行 评选，而今年的评选更是强化了数据维度。《财富》杂志首次采用更复杂的评分系统，除了基于业务指 标（涵盖12个月和三年周期数据），还结合高管的影响力、创新能力、职业轨迹以及为改善业务所做的 努力等维度为候选人赋值。该系统更倾向于首席执行官群体，因此，部分担任其他高管职位的上榜者在 榜单上的排名较往年有所下滑。 随着更多女性执掌举足轻重的企业，这份榜单的竞争变得更加激烈。今年排名前三位的分别是：蝉联榜 首的通用汽车公司首席执行官玛丽·巴拉（Mary Barra）、埃森哲首席执行官朱莉·斯威特（Julie Sweet） 和花旗集团首席执行官简·弗雷泽（Jane Fraser）。此外，还有来自沃尔玛、Netflix等全球顶尖企业的资 深领导者。 略超半数的上榜女性在美国工作，美国在推动女性登上企业最高层方面仍然大幅领先其他国家；其余48 位上榜者来自其他国家，覆盖19个国家和地区。紧随美国之后 ...

Company Overview - KANZHUN LIMITED operates the leading online recruitment platform BOSS Zhipin in China, connecting job seekers and enterprise users through a highly interactive mobile app that promotes two-way communication and intelligent recommendations [5]. Annual General Meeting (AGM) - The Company will hold its annual general meeting of shareholders on June 27, 2025, at 3 p.m. Beijing time, to consider proposed resolutions [1]. - Shareholders and holders of American depositary shares (ADSs) are encouraged to vote in favor of the proposed resolutions as recommended by the board of directors [1]. Voting Rights - Holders of record of ordinary shares and ADSs as of May 22, 2025, are entitled to notice of, attend, and vote at the AGM [2]. Financial Reporting - The Company has filed its annual report on Form 20-F, including audited financial statements for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC) [3].

Group 1 - The article presents the market capitalization changes of global automotive manufacturers as of May 22, 2025, highlighting significant fluctuations in their valuations [1][3][4] - BMW's market capitalization stands at $555.1 billion, experiencing a decrease of 1.95% [3] - Porsche's market capitalization is reported at $475.13 billion, with a decline of 2.05% [3] - General Motors has a market capitalization of $474.66 billion, down by 8.06% [3] - The market capitalization of Mahindra & Mahindra is $433.59 billion, showing an increase of 3.82% [3] - Honda's market capitalization is $420.95 billion, reflecting a rise of 3.26% [3] - Ford's market capitalization is $416.74 billion, with a significant drop of 9.55% [3] - Hyundai's market capitalization is $348.13 billion, up by 9.84% [3] - Tata Motors has a market capitalization of $312.89 billion, increasing by 3.4% [3] - The market capitalization of Li Auto is $296.46 billion, with a notable increase of 8.86% [3] Group 2 - The article also lists other automotive manufacturers, such as Nissan with a market capitalization of $86.86 billion, down by 1.97% [4] - Renault's market capitalization is $162.33 billion, showing a slight increase of 0.73% [4] - Changan Automobile has a market capitalization of $154.73 billion, up by 2.42% [4] - Subaru's market capitalization is $133.5 billion, reflecting a decrease of 2.57% [4] - VinFast Auto's market capitalization is $82.56 billion, with a minor decline of 0.23% [4]

Group 1 - Dollar General Corporation's shares are experiencing a decline after a previous gain of over 4%, but there is potential for a rally to resume and prices to increase [1] - The stock has recently broken out, indicating a bullish trend, as it has surpassed a resistance level where selling interest was previously high [1][3] - If the stock remains above the former resistance level, it suggests that sellers have exited the market, potentially leading to further price increases as new buyers enter [4] Group 2 - Dollar General is approaching price levels that it previously gapped down through, indicating a lack of trading interest at those levels, which may result in fewer sellers if the stock returns to those prices [7] - Buyers will need to be aggressive to acquire shares, which could lead to a rapid upward movement in price as the gap refills [8]

Group 1 - General Motors (GM) has decided to stop exporting vehicles from the United States to China amid ongoing trade negotiations between the two countries [1] - The Durant Guild, GM's premium import brand, accounted for less than 0.1% of total sales in China, prompting a restructuring of operations due to significant economic shifts [2] - In Q1 2025, GM and its joint ventures delivered over 442,000 vehicles in China, achieving year-over-year sales growth and increasing market share for the third consecutive quarter [3] Group 2 - Sales of new energy vehicles (NEVs) in China surged by 53.2% year-over-year, with GM planning to expand its NEV portfolio further in 2025 [3] - Ford Motor Company has also paused shipments of several U.S.-built vehicles to China due to retaliatory tariffs, which have increased import taxes significantly [4] - Tesla halted new orders for its Model S and Model X in China following increased tariffs on U.S. imports, facing rising competition from domestic manufacturers like BYD [5]

跨国车企正调整电动汽车短、中、长期投入。 全球电动汽车市场的变化以及来自财务的压力，正影响着跨国车企短中长期业务布局。 日前，本田宣布，将调整纯电动汽车（EV）战略，即到2030年度，原计划用于纯电动汽车和软件开发 的10万亿日元将降至7万亿日元，降幅30%。 与此同时，本田还将缩减纯电动汽车销量。本田社长三部敏宏还表示，本田将修正截至2030年的纯电动 汽车在汽车销量中所占的比例，预计从此前的40%调整到30%以下。 同时，福特决定推迟下一代电动车型的推出，包括原计划2026年发布的中型电动皮卡，已延期至2027年 底；并取消一款原计划2025年推出的三排座纯电SUV的开发，该车型原定于2027年推出，但因无法实现 盈利目标而被砍掉，导致公司损失19亿美元。福特首席财务官约翰·劳勒解释称，公司在评估市场竞 争、消费者需求以及电动车电池成本后发现，该车型无法在上市第一年内实现盈利，因此决定终止该项 目。 通用汽车在2024年6月已下调了当年电动汽车产量预测。通用汽车首席执行官玛丽·博拉表示，由于市场 尚未成熟，通用汽车到2025年底不会在北美生产100万辆电动汽车，但公司仍致力于实现这一目标。此 外，通用汽车 ...